Metabolic Disease
| 4 min read
The FDA’s National Priority Voucher program aims to cut standard review times from potentially years to months, raising questions about safety, access, and public health impact.
| 3 min read
Novo Nordisk’s Phase 3 trials revealed that oral semaglutide failed to slow the progression of disease.
| 3 min read
A gene therapy targeting ANTIGPTL3 reduced cholesterol and triglyceride levels simultaneously.
| 5 min read
Explore the mechanisms, clinical applications, and future opportunities of GLP-1 receptor agonists in drug development and disease management.
| 6 min read
By combining 3D biofabrication with perfusable vasculature, researchers are paving the way for fully implantable organs.
| 7 min read
With blockbuster status secured, GLP-1 therapies face new questions about efficacy, delivery, and their role in treating multiple chronic diseases.
| 3 min read
The kidney structures replicate newborn-level maturity, enabling studies of complex disease features such as fibrosis and drug toxicity.
| 2 min read
Researchers showed that in rodent models, a glia-produced molecule could regulate weight loss and glucose metabolism without gastrointestinal symptoms.
| 2 min read
EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedema.
| 4 min read
Researchers showed that insulin resistance exists on a spectrum among diabetics and healthy controls.
| 4 min read
Explore the link between GLP-1 drugs and cancer. A new study reveals these therapies may reduce the risk of obesity-related cancers, similar to bariatric surgery.
| 5 min read
Explore how the gut microbiome impacts health. Learn about a new study that reveals how a specific microbe, P. faecium, may help fight obesity.
